NF1 and plexiform neurofibroma: A new systemic treatment option—selumetinib, a MEK inhibitor—has been approved for NF1 by the FDA (2020) and EMA (2021), which is mainly used for symptomatic, inoperable plexiform neurofibromas in children [6,28].